230
Views
7
CrossRef citations to date
0
Altmetric
Reviews

Rodent models for the preclinical evaluation of drugs suitable for pharmacological intervention in aging

, , , , , , , , , , , , , & show all
Pages 85-95 | Published online: 01 Dec 2011

Bibliography

  • Andrews GR, Sidorenko A, Andrianova LF, The United Nations research agenda on ageing for the 21st century. Adv Gerontol 2001;7:7-25
  • FUTURAGE: A Road Map for European Ageing Research, October 2011. Available from: www.futurage.group.shef.ac.uk/road-map.html
  • Rae MJ, Butler RN, Campisi J, The demographic and biomedical case for late-life interventions in aging. Sci Transl Med 2010;2(1):40cm21
  • Anisimov VN. Molecular and Physiological Mechanisms of Aging. Volume 1 & 2 Nauka; St.Petersburg: 2008
  • Anisimov VN. Life span extension and cancer risk: myths and reality. Exp Gerontol 2001;36:1101-36
  • Anisimov VN. Premature ageing prevention: limitations and perspectives of pharmacological interventions. Curr Drug Res 2006;7:1485-504
  • Rattan SIS. editor. Aging Interventions and Therapies. World Scientific Publishing Co.Pte.Ltd; New Jersey: 2005
  • Hefti FF, Bales R. Regulatory issues in aging pharmacology. Aging Cell 2006;5:3-8
  • Kirkland JL, Peterson C. Healthspan, translation, and new outcomes for animal studies of aging. J Gerontol Biol Sci 2009;64A:209-12
  • Spindler SR. Review of the literature and suggestion for the design of rodent survival studies for the identification of compounds that increase health and life span. AGE doi10.1007/s11357-011-224-6
  • Tollefsbol TO. Biological Aging: Methods and Protocols. Humana Press, Totowa,; New Jersey: 2007
  • Khabriev RU. editor. Manual on Experimental (Preclinical) Study of New Pharmacological Compounds. 2nd edition. Meditsina Publ; Moscow: 2005
  • Ingram DK, Jucker M. Developing mouse models of aging: a consideration of strain differences in age-related behavioral and neural parameters. Neurоbiol Aging 1999;20:137-45
  • Maronpot RR, Flake G, Huff J. Relevance of animal carcinogenesis findings to human cancer predictions and prevention. Toxicol Pathol 2004;32(Suppl 1):40-8
  • Anisimov VN, Ukraintseva SV, Yashin AI. Cancer in rodents: does it tell us about cancer in humans? Nat Rev Cancer 2005;5:807-19
  • Jackson Laboratories Strain Information. Available from: http:/jaxmice.jax.org.jaxmicedb/html. inbred/shtml
  • Nadon NL. Exploiting the rodent model for studies on the pharmacology of lifespan extension. Aging Cell 2006;5:9-15
  • Anisimov VN. Spontaneous tumors in rats of various strains. Vopr Onkol 1976;22(8):98-110
  • Anisimov VN. Carcinogenesis and Aging. Volume 1 CRC Press; Boca Raton: 1987
  • Smith GS, Walford RL, Mickey HR. Lifespan and incidence of cancer and other diseases in selected long-lived inbred mice and their F1 hybrids. J Natl Cancer Inst 1973;50:1195-213
  • Ward JM. Background data and variations in tumor rates of control rats and mice. Prog Exp Tumor Res 1983;26:241-58
  • Teicher BA. editor. Tumor Models in Cancer Research. Humana Press; New Jersey: 2003
  • Anisimov VN, Popovich IG, Zabezhinski MA, Melatonin as antioxidant, geroprotector and anticarcinogen. Biochim Biophys Acta 2006;1757:573-89
  • Anisimov VN. Metformin for aging and cancer prevention. Aging (Albany, NY) 2010;2:760-74
  • Anisimov VN, Berstein LM, Egormin PA, Metformin slows down aging and extends life span of female SHR mice. Cell Cycle 2008;7:2769-73
  • Snyder DL, Pollard M, Wostmann BS, Lackert P. Life span, morphology, and pathology of diet-restricted germ-free and conventional Lobund-Wistar rats. J Gerontol 1990;52:B52-8
  • Anisimov VN, Popovich IG, Zabezhinski MA. Models and methods of study on geroprotective activity of pharmacological preparations. Adv Gerontol 2009;22:237-52
  • Anisimov VN, Popovich IG, Zabezhinski MA. Methods of evaluating the effect of pharmacological drugs on aging and life span in mice. In: Tollefsbol TO, editor. Biological Aging: Methods and Protocols (Methods in Molecular Biology; volume 371). Humana Press; Totowa, New Jersey: 2007. p. 227-36
  • Montesano R, Bartsch H, Vainio H, Long-term and short-term assays for carcinogens: a critical appraisal. IARC Sci Publ No 83; ; Lyon: 1986
  • Anisimov VN. Aging and cancer in transgenic and mutant mice. Front Biosci 2003;8:S883-902
  • Turusov VS, Parfenov YD. Revealing and specification of chemical carcinogens. Meditsina; Moscow: 1986
  • Smyth RD, Hottendorf GH. Application of pharmacokinetics and biopharmaceutics in design of toxicological studies. Toxicol Appl Phramacol 1980;53:179-95
  • Rhomberg LR, Baetcke K, Blancato J, Issues in the design and interpretation of chronic toxicity and carcinogenicity studies in rodents: approaches to dose selection. Crit Rev Toxicol 2007;37:729-37
  • Arutjunyan AV, Dubinina EE, Zybina NN. Methods of evaluation of free radical oxidation and of antioxidase system of the organism. Methodical recommnedations. Foliant; St.Petersburg: 2000
  • Rozenfeld SV, Togo EF, Mikheev VM, Age-associated dynamics of chromosome aberration incidence in male mice of different strains. Bull Exp Biol Med 2001;131:568-70
  • Garcia AM, Busutti RA, Rodriguez A, Detection and analysis of somatic mutations at a lacZ reporter locus in higher organisms: application to Mus musculus and Drosophila melanogaster. Methods Mol Biol 2007;371:267-88
  • Canela A, Klatt P, Blasco MA. Telomere length analysis. Methods Mol Biol 2007;371:45-72
  • Anisimov SV. Application of DNA microarray technology to gerontological studies. Methods Mol Biol 2007;371:249-66
  • Gart JJ, Krewski D, Lee PN, Statistical Methods in Cancer Research. Volume 3 The Design and Analysis of Long-Term Animal Experiments. IARC Sci Publ No 79; Lyon: 1986
  • Turusov VS, Mohr U. editors. Pathology of Tumours in Laboratory Animals. Volume 1 Tumours of the Rat. 2nd edition. IARC Sci Publ No 99; Lyon: 1990
  • Turusov VS, Mohr U. editors. Pathology of Tumours in Laboratory Animals. Volume 2 Tumours of the Mouse. 2nd edition. IARC Sci Publ No 111; Lyon: 1993
  • Marchuk GI, Anisimov VN, Romanyukha AA, Yashin AI. Gerontology in silico: Establishment of New Discipline. Mathematical Models, Data Analysis and Calculation Experiments. Publ.BINOM; Moskow: 2007
  • Warner HR, Ingram D, Miller RA, Program for testing biological interventions to promote health aging. Mech Ageing Dev 2000;155:199-208
  • Miller RA, Harrison DE, Astle CM, An Aging Intervention Testing Program: stuffy design and interim report. Aging Cell 2007;6:565-75
  • Miller RA, Nadon NL. Principle of animal use for gerontological research. J Gerontol A Biol Sci Med Sci 2000;55:B117-23
  • Harrison DE, Strong R, Sharp ZD, Rapamycin fed late in life extends lifespan in genetically heterogenous mice. Nature 2009;460:392-6
  • Vainio H, Magee P, McGregor D, McMichael AJ. editors. Mechanisms of Carcinogenesis in Risk Identification. IARC Sci Publ No 116; Lyon: 1986
  • Korkushko OV, Khavinson VKh, Butenko GM, Shatilo VB. Peptide Preparations of Thymus and Pineal Gland in Prevention of Accelerated Aging. Nauka; St.Petersburg: 2002
  • Zabezhinski MA, Anisimov VN, Popovich IG, Methodology of modern approaches to the evaluation of oncological risk and to reglamentation of chemical carcinogens. In: Merabishvili VM, editor. Oncological Statistics (Tradition Methods, New Information Technology): Manual for Physician. Part II. Publ.Complex KOSTA; St.Petersburg: 2011. p. 175-99
  • Аnisimov VN. Carcinogenesis and aging 20 years after: Escaping horizon. Mech Ageing Dev 2009;130:105-21
  • National Toxicology Program. Report on the NTP ad hoc Panel on Chemcal Carcinogenesis Testing and Evaluation. US Department of Health and Human Services; Washington, DC: 1984
  • Solleveld HA, McConneell EE. The value and significance of life span and scheduled termination data in long-term toxicity and carcinogenesis studies. Toxicol Pathol 1985;13:128-34
  • Stukov AN, Gershanovich ML, Blank MA, Anti-Tumor Drugs. NIKA; St.Petersburg: 2011
  • Anikin IV, Pliss GB, Vlasov NN. Use of autochthonous neoplasia of animals in experimental therapy of tumors. Vopr Onkol 1993;4-6:161-8
  • Amberger H. Different autochthonous models of colorectal cancer in the rat. J Cancer Res Clin Oncol 1986;111:157-9
  • Meyskens FL, Curt GA, Brenner DE, Chemoprevention Clinical Trials and biomarkers subcommittee regulatory approval of cancer risk-reducing (chemopreventive) drugs: moving what we have learned into the clinic. Cancer Prev Res 2011;4:311-23
  • Naithani R, Huma LC, Moriarty RM, Comprehensive review of cancer chemopreventive agents evaluated in experimental carcinogenesis models and clinical trials. Curr Med Chem 2008;15:1044-71
  • Popovich IG, Zabezhinski MA, Anisimov VN. Method of detection of anticarcinogenic activity of drugs in vivo (Guidelines for physicians). Petrov Res. Institute of Oncology Publ; St.Petersburg: 2003
  • Bespalov VG. Cancer chemoprevention. Practical Med 2007;2:73-4
  • Anisimov VN, Ames BN, Arkind R, The 54 Scientists' Open Letter on Aging Research 2006. Available from: http://ieet.org/index.php/IEET/more/scientistsantiaging/

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.